ClinicalTrials.gg
CompletedNCT04491838Updated Mar 23, 2021

Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants

A Phase 1 interventional study of Pozelimab in Healthy Volunteer, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-23.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2021, 5 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary objective of the study is to compare the pharmacokinetic(PK) profile of pozelimab produced by the original manufacturing process (Process A) compared to a second manufacturing process (Process B)

The secondary objectives of the study are:

  • Assess the safety and tolerability of a single SC dose of pozelimab produced by the 2 manufacturing processes
  • Assess the immunogenicity of pozelimab produced by the 2 manufacturing processes
02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Has a body weight of 55 kg to 100 kg and a between 18 kg/m2 and 30 kg/m2 inclusive at the screening visit
  • Judged to be in good health based on medical history, physical examination, vital signs measurements, and performed at screening and/or prior to administration of initial dose of study drug
  • Is in good health based on laboratory safety testing obtained at the screening visit. NOTE: Subject with a history of Gilbert's disease can be enrolled in the study
  • Willing to undergo vaccination against N meningitidis unless subjects have documentation of completed series of vaccinations within the past 2 years of the screening visit
  • Must have two negative COVID-19 tests within 7 days prior to study drug administration as defined in the protocol

Key Exclusion Criteria:

  • History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or neurological disease, as assessed by the investigator
  • Hospitalization (>24 h) for any reason within 90 days of the screening visit
  • Has a confirmed positive drug test result at the screening visit and/or prior to enrollment; and/or a history of recreational drug use (eg, marijuana) and/or drug or alcohol abuse within a year prior to the screening visit
  • Is positive for , , or antibody as defined in the protocol
  • Known or suspected COVID-19 disease
  • History of tuberculosis, systemic fungal diseases, or meningococcal infection
  • Known allergy or intolerance to penicillin class antibiotics or macrolides; any to azrithromycin per local prescribing information

Note: Other protocol-defined Inclusion/ Exclusion criteria apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Process A

    Randomized 1:1

    Drug: Pozelimab

  • Experimental
    Process B

    Randomized 1:1

    Drug: Pozelimab

Interventions

  • Single subcutaneous (SC) injection

    Also known as: REGN3918

06

What researchers measure

Primary outcomes

  1. Assess the time of the last positive concentration (AUClast) pharmacokinetic (PK) profile of pozelimab in Process A

    Time frame: Up to 16 weeks

  2. Assess the time of the last positive concentration (AUClast) PK profile of pozelimab in Process B

    Time frame: Up to 16 weeks

  3. Assess peak concentration (Cmax) PK profile of pozelimabin in Process A

    Time frame: Up to 16 weeks

  4. Assess peak concentration (Cmax) PK profile of pozelimab in Process B

    Time frame: Up to 16 weeks

Secondary outcomes

  1. Incidence of treatment emergent adverse events (TEAEs)

    Time frame: Up to 16 weeks

  2. Incidence of anti-drug antibodies (ADA) to pozelimab over time

    Time frame: Up to 16 weeks

07

Study locations

1 site
  • Regeneron Study Site
    Antwerpen, B-2060, Belgium
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Mar 2021, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2020
First posted
Jul 29, 2020
StartActual
Aug 3, 2020
Primary completionActual
Mar 5, 2021
CompletionActual
Mar 5, 2021
Last update
Mar 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04491838
Responsible party
Sponsor
First posted
Jul 29, 2020
Start date
Aug 3, 2020
Primary completion
Mar 5, 2021
Completion
Mar 5, 2021
Last update
Mar 23, 2021

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pozelimab

Start the discussion